A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

被引:45
|
作者
Wu, Xiujuan [1 ]
Tang, Peng [1 ]
Li, Shifei [1 ]
Wang, Shushu [1 ]
Liang, Yueyang [1 ]
Zhong, Ling [1 ]
Ren, Lin [1 ]
Zhang, Ting [1 ]
Zhang, Yi [1 ]
机构
[1] Third Mil Med Univ, Southwest Hosp, Breast Dis Ctr, Chongqing 400038, Peoples R China
来源
NATURE COMMUNICATIONS | 2018年 / 9卷
关键词
PATHOLOGICAL COMPLETE RESPONSE; ARTERIAL CHEMOEMBOLIZATION; ANTITUMOR-ACTIVITY; CHEMOTHERAPY; DOCETAXEL; CARBOPLATIN; EPIRUBICIN; PACLITAXEL; CISPLATIN; DOXORUBICIN;
D O I
10.1038/s41467-018-03210-2
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patients (63 TE and 62 TEL patients). Four patients did not complete all the cycles. Two-sided P values show that the addition of L (38.7% vs. 12.7%, P = 0.001) significantly increases the rate of pCR in the breast and the axilla (TpCR) and the overall response rate (ORR; 93.5% vs. 73.0%, P = 0.003). The occurrence of grade 3-4 anemia and thrombocytopenia is higher in the TEL group (52.5% vs. 10.0% and 34.4% vs. 1.7% respectively). These results demonstrate that the addition of L to the TE regimen as neoadjuvant chemotherapy improves the TpCR and the ORR rates of TNBC but with increased side effects.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Efficacy and safety of sintilimab plus XELOX as neoadjuvant therapy in patients with locally advanced gastric cancer: A single-arm open-label phase II trial.
    Guo, Honghai
    Ding, Ping'an
    Yang, Peigang
    Tian, Yuan
    Liu, Yang
    Zhang, Ze
    Zheng, Tao
    Zhang, Zhidong
    Wang, Dong
    Tan, Bibo
    Zhao, Xuefeng
    Li, Yong
    Zhao, Qun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16091 - E16091
  • [42] A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC).
    Rimawi, Mothaffar F.
    Aleixo, Sabina B.
    Rozas, Ashley Alarcon
    Matos Neto, Joao Nunes
    Caleffi, Maira
    Vinholes, Jeferson J. F.
    Figueira, Alicardo Cesar
    Souza, Sulene Cunha
    Reiriz, Andre B.
    Arantes, Heloisa
    Uttenreuther-Fischer, Martina Maria
    Osborne, C. Kent
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] NivoCUP: An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary.
    Tanizaki, Junko
    Yonemori, Kan
    Akiyoshi, Kohei
    Minami, Hironobu
    Ueda, Hiroki
    Takiguchi, Yuichi
    Kondoh, Chihiro Nakayama
    Segawa, Yoshihiko
    Takahashi, Shin
    Iwamoto, Yasuo
    Kidera, Yasuhiro
    Fukuoka, Kazuya
    Nakamura, Yasushi
    Chiba, Yasutaka
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    Hayashi, Hidetoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Open-label Phase II trial of ozoralizumab produces promising results
    Fitzpatrick, Sean
    IMMUNOTHERAPY, 2012, 4 (08) : 760 - 760
  • [45] Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: A phase II randomized trial
    Hornsby, Whitney E.
    Douglas, Pamela S.
    West, Miranda J.
    Kenjale, Aarti A.
    Lane, Amy R.
    Schwitzer, Emily R.
    Ray, Kaitlin A.
    Herndon, James E., II
    Coan, April
    Gutierrez, Antonio
    Hornsby, Kyle P.
    Hamilton, Erika
    Wilke, Lee G.
    Kimmick, Gretchen G.
    Peppercorn, Jeffrey M.
    Jones, Lee W.
    ACTA ONCOLOGICA, 2014, 53 (01) : 65 - 74
  • [46] A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis
    Morgan, Timothy
    Asghar, Aliya
    Tayek, John
    Nguyen, Danh
    Fleischman, M. Wayne
    Donovan, John
    Alcorn, Joseph
    Chao, Daniel
    Stolz, Andrew
    JOURNAL OF HEPATOLOGY, 2022, 77 : S142 - S142
  • [47] Apatinib in Chinese patients with advanced hepatocellular carcinoma: A phase II randomized, open-label trial.
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [48] A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis
    Tayek, John A.
    Stolz, Andrew A.
    Nguyen, Danh, V
    Fleischman, M. Wayne
    Donovan, John A.
    Alcorn, Joseph M.
    Chao, Daniel C-K
    Asghar, Aliya
    Morgan, Timothy R.
    ECLINICALMEDICINE, 2022, 54
  • [49] An open-label, phase II trial of cabozantinib for advanced adrenocortical carcinoma
    Campbell, M. T.
    Jimenez, C.
    Long, J. P.
    Varghese, J.
    Shah, A.
    Zhang, M.
    Tamsen, G.
    Habra, M. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S545 - S545
  • [50] Open-label placebo reduces fatigue in cancer survivors: a randomized trial
    Eric S. Zhou
    Kathryn T. Hall
    Alexis L. Michaud
    Jaime E. Blackmon
    Ann H. Partridge
    Christopher J. Recklitis
    Supportive Care in Cancer, 2019, 27 : 2179 - 2187